X0609 4 2026-06-30 false 0001782223 Pyxis Oncology, Inc. PYXS 0001553335 Dupont Jakob false C/O PYXIS ONCOLOGY, INC. 321 HARRISON AVENUE, 11TH FL. SUITE 1 BOSTON MA 02118 true false false false true Common Stock 2026-06-30 4 M false 35000 1.6 A 73741 D Common Stock 2026-06-30 4 S false 35000 3.06 D 38741 D Stock Option (Right to Buy) 1.6 2026-06-30 4 M false 35000 0 D 2033-09-22 Common Stock 35000 357461 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025. Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4. The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36. Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). /s/ Jitendra Wadhane, Attorney-in-Fact for Jakob Dupont 2026-07-02